Ratz, Leonie http://orcid.org/0000-0002-4783-987X
Brambillasca, Chiara
Bartke, Leandra
Huetzen, Maxim A.
Goergens, Jonas
Leidecker, Orsolya
Jachimowicz, Ron D.
van de Ven, Marieke
Proost, Natalie
Siteur, Bjørn
de Korte-Grimmerink, Renske
Bouwman, Peter
Pulver, Emilia M.
de Bruijn, Roebi
Isensee, Jörg
Hucho, Tim
Pandey, Gaurav
van Lohuizen, Maarten
Mallmann, Peter
Reinhardt, Hans Christian
Jonkers, Jos
Puppe, Julian
Funding for this research was provided by:
German-Israeli Foundation for Scientific Research and Development (I-65-412.20-2016)
Deutsche Forschungsgemeinschaft (SFB-1399, A01/C02, KFO-286-RP2, RE 2246/13-1)
José Carreras Leukämie-Stiftung (R12/08)
Else Kröner-Fresenius-Stiftung (EKFS-2014-A06, 2016_Kolleg.19)
Deutsche Krebshilfe (1117240, 70113041, 70113307)
Bundesministerium für Bildung und Forschung (BMBF e:Med 01ZX1303A)
Universität zu Köln (Gerok rotation position, Köln Fortune position)
KWF Kankerbestrijding (NKI 2015-7877)
Lundbeckfonden (R223-2016-956)
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO Vici project 91814643, NWO Mosaic program grant 017.008.022)
Universitätsklinikum Köln
Article History
Received: 2 June 2021
Accepted: 1 June 2022
First Online: 17 June 2022
Declarations
:
: This study is compliant with all relevant ethical regulations regarding animal research. All animal experiments were approved by the Animal Ethics Committee of The Netherlands Cancer Institute (Amsterdam, the Netherlands) and performed in accordance with the Dutch Act on Animal Experimentation.
: All authors revised and approved the final manuscript.
: H.C.R. received consulting and lecture fees from Abbvie, AstraZeneca, Vertex and Merck. H.C.R. received research funding from Gilead Pharmaceuticals. H.C.R. is a co-founder of CDL Therapeutics GmbH. The remaining authors declare no competing financial interest.